Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana

Vaccine

Volumn 16, Issue 9-10, 1998, Pages 1043-1052

  González, César R ^a   Noriega, Fernando R ^b   Huerta, Sara ^a   Santiago, Araceli ^a   Vega, Mario ^a   Paniagua, Jorge ^a   Ortiz Navarrete, Vianney ^a   Isibasi, Armando ^a   Levine, Myron M ^b  

^a U de Invest Med en Genet Humana   (Mexico)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

gp63; Leishmania mexicana; Salmonella typhi; Vector vaccines

Indexed keywords

PLASMID VECTOR;

ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CYTOKINE RELEASE; GENE EXPRESSION; IMMUNIZATION; IMMUNOGENICITY; LEISHMANIA MEXICANA; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; SALMONELLA TYPHI; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, PROTOZOAN; BASE SEQUENCE; CYTOTOXICITY, IMMUNOLOGIC; DNA PRIMERS; GENES, PROTOZOAN; GENETIC VECTORS; HUMANS; INTERLEUKIN-2; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; LYMPHOCYTE ACTIVATION; METALLOENDOPEPTIDASES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; SALMONELLA TYPHI; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 0032078757     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00267-3     Document Type: Article

References (61)

1. 1 The leishmaniasis, Technical report series, no. 701 (report of a WHO Expert Committee). World Health Organization, Geneva, 1984, pp. 10-14.
2. 2 Goodwin, L.G. Chemotherapy - overview. In: Leishmaniasis, the Current Status and New Strategies for Control (Ed. Hart, D.T.), NATO ASI series. Plenum Press, New York, 1989, pp. 693-697.
3. 3 Alexander, J. and Russell, D. Parasite antigens, their role in protection, diagnosis and scape: the leishmaniasis. Curr. Top. Microbiol. Immunol. 1985, 129, 43-67.
4. 4 Alexander, J. A radioattenuated L. major vaccine markedly increases resistance of CBA mice to subsequent infection with L. m. mexicana. Trans. R. Soc. Trop. Med. Hyg. 1982, 76, 646-649.
5. 5 Handman, E. and McConville, M.J. Vaccines against Leishmania. In: New Generation Vaccines (Eds Woodrow, G.C. and Levine, M.M.). Marcel Dekker, New York, 1989, pp. 545-564.
6. 6 Liew, F.Y. Leishmaniasis, In: Vaccination Strategies of Tropical Diseases (Eds Liew, F.Y.). CRL Press, Boca Raton, FL, 1989, pp. 239-253.
7. 7 Howard, J.G., Nicklin, S., Hale, C. and Liew, F.Y. Prophylactic immunization against experimental leishmaniasis. J. Immunol. 1982, 129, 2206-2212.
8. 8 Liew, F.Y., Hale, C. and Howard, J.G. Prophylactic immunization against experimental leishmaniasis. J. Immunol. 1985, 135, 2102-2107.
9. 9 Titus, R., Marchand, M., Milon, G., Marchal, G., Boon, T. and Louis, J. Cutaneous leishmaniasis: relative role of T cell subsets. Adv. Exp. Med. Biol. 1988, 238, 121-134.
10. 10 Bouvier, J.R., Etges, R.J. and Bordier, C. Identification of the promastigote surface protease in seven species of Leishmania. Mol. Biochem. Parasitol. 1987, 24, 73-79.
11. 11 Button, L. and McMaster, W.R. Molecular cloning of the surface antigen of Leishmania. J. Exp. Med. 1988, 167, 724-729.
12. 12 Colomer-Gould, V., Quintao, L.G., Keithly, J. and Nogueira, N. A common major surface antigen on amastigotes and promastigotes of Leishmania species. J. Exp. Med. 1985, 162, 902-916.
13. 13 Etges, R.J., Bouvier, J. and Hoffman, R. Evidence that the major surface proteins of three Leishmania species are structurally related. Mol. Biochem. Parasitol. 1985, 14, 141-149.
14. 14 Medina-Acosta, E., Karess, R.E. and Rusell, D.G. Structurally distinct genes for the surface protease of Leishmania mexicana are developmentally regulated. Mol. Biochem. Parasitol. 1993, 57, 31-45.
15. 15 Russell, D.G. and Alexander, J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J. Immunol. 1988, 140, 1274-1279.
16. 16 Xu, D., Mcsorley, S.J., Chatfield, S.N., Dougan, G. and Liew, F.Y. Protection against Leishmania major infection in genetically susceptible BALC/c mice by GP63 delivered orally in attenuated Salmonella typhimurium (Aro AroD). Immunology 1995, 85, 1-7.
17. -) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J. Immunol. 1990, 145, 2281-2285.
18. 18 Connell, N.D., Medina-Acosta, E., McMaster, W.R., Bloom, B.R. and Russell, D.G. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63. Proc. Natl. Acad. Sci. USA 1993, 90, 11473-11477.
19. 19 Abdelhak, S., Louzir, H. and Timm, J. et al. Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology 1995, 141, 1585-1592.
20. 20 Xu, D. and Liew, F.Y. Genetic vaccination against leishmaniasis. Vaccine 1994, 12, 1534-1536.
21. 21 Muller, I., Pedrazzini, T., Farrell, J.P. and Louis, J. T-cell responses and immunity to experimental infection with Leishmania major. Ann. Rev. Immunol. 1989, 7, 561-578.
22. 22 Sadick, M.D., Locksley, R.M., Tubbs, and Cawand Raff, H.V. Murine cutaneous Leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro. J. Immunol. 1986, 136, 655-661.
23. 23 Scott, P., Natovitz, P., Coffman, R.L., Pearce, E. and Sher, A. Immunoregulation of cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J. Exp. Med. 1988, 168, 1675-1684.
24. 24 Kemp, M., Hey, S. and Kurtzhals, J.A.L. et al. Dichotomy of the human T cell response to Leishmania antigens. I. Th1 like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clin. Exp. Immunol. 1994, 96, 410-415.
25. 25 Kurtzhals, J.A.L., Hey, A.S. and Jardim, A. et al. Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients. Clin. Exp. Immunol. 1994, 96, 416-421.
26. 26 Melby, P.C., Andrade-Narvaez, F.J., Darnell, B.J., Valencia-Pacheco, G., Tryon, V.V. and Palomo-Cetina, A. Increased expression of proinflamatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect. Immun. 1994, 62, 837-842.
27. 27 Heinzel, F.P., Schoenhaut, D.S., Rerko, R.M. and Gately, M.K. Recombinant Interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 1993, 177, 1505-1509.
28. 28 Sypek, J.P., Chung, Ch.L. and Mayor, E.H. et al. Resolution of cutaneous Leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J. Exp. Med. 1993, 177, 1797-1802.
29. 29 Bogdan, C., Gessner, A., Solbach, W. and Röllinhoff, M. Invasion, control and persistence of Leishmania parasites. Curr. Op. Immunol. 1996, 8, 517-525.
30. 30 Heinzel, F.P., Sadick, M.D., Holaday, B.J., Coffman, R.L. and Locksley, R.M. Reciprocal expression of interferon-gamma or IL-4 during the resolution or progression of murine leishmaniasis. J. Exp. Med. 1989, 169, 59-72.
31. 31 Mocci, S. and Coffman, R. Induction of a Th2 population from polarized Leishmania-specific Th1 population by in vitro culture with IL-4. J. Immunol. 1995, 154, 3779-3787.
32. 32 Wershil, B.K., Theodos, C.M., Galli, S.P. and Titus, R.G. Mast cells augment lesion size and persistence during experimental Leishmania major infection in the mouse. J. Immunol. 1994, 152, 4563-4570.
33. 33 Fouts, T.R., Lewis, G.K. and Hone, D.M. Construction and characterization of a Salmonella-based HIV-1 vector vaccine. In: Vaccines 93. Modern approaches to new vaccines including prevention of AIDS (Eds Ginsberg, H.S., Brown, F., Chanock, R.M. and Lerner, R.A.). Cold Spring Harbor, New York, 1993, pp. 95-99.
34. 34 Giron, J.A., Xu, J.-G., Gonzalez, C.R., Hone, D.M., Kaper, J.B. and Levine, M.M. Simultaneous expression of CFA/I and CS3 colonization factor antigens of enterotoxigenic Escherichia coli by ΔaroC, ΔaroD Salmonella typhi vaccine strain CVD 908, Vaccine 1995, 13, 939-946.
35. 35 González, C., Hone, D. and Noriega, F. et al. Salmonella typhi strain CVD 908 expressing the circumsporozoitic protein of Plasmodium falciparum: strain construction, safety and immunogenicity in humans. J. Infect. Dis. 1994, 169, 927-931.
36. 36 Monroy-Ostria, A., Fuentes-Fraga, I., García-Flores, C. and Favila-Castillo, L. Infection of BALB/c, C57BI/6 mice with strains of Leishmania mexicana isolated from Mexican patients with localized or diffuse cutaneous leishmaniasis. Arch. Invest. Med. (Méx.) 1994, 25, 401-406.
37. 37 Ganong, B.R. and Delmore, J.P. Phase separation temperatures of mixtures of Triton X-114 and Triton X-45: application to protein separation. Anal. Biochem. 1991, 193, 35-37.
38. 38 Engvall, E. and Perlmann, P. Enzyme-linked immunosorbent assay (ELISA). Immunochemistry 1971, 8, 874-979.
39. 39 Miller, V.L. and Mekalanos, J.J. A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR. J. Bacteriol. 1988, 170, 2575-2583.
40. 40 Hone, D.M., Harris, A., Chatfield, S., Dougan, G. and Levine, M.M. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine 1992, 8, 810-816.
41. 41 Saiki, R.K., Gelfand, D.H. and Stoffel, S. et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988, 239, 487-491.
42. 42 Lowry, O.H., Rosenbrough, N.J., Farr, A.L. and Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
43. 43 Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227, 680-685.
44. 44 Towbin, H., Staehelin, T. and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets; procedure and some applications. Proc. Natl. Acad. Sci. USA 1979, 76, 4350-4354.
45. 45 Momburg, F., Ortiz-Navarrte, V. and Neefjes, J. Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation. Nature 1992, 360, 174-177.
46. 46 Sambrook, K.J., Fritch, E.F. and Maniatis, T. Molecular Cloning, a laboratory manual. Cold Spring Harbor Laboratory Press, USA, 1989, pp. 1.42-1.46.
47. 47 Gonzalez, C.R., Isibasi, A. and Ortiz-Navarrete, V. et al. Lymphocytic proliferative response to outer membrane proteins isolated from Salmonella. Microbiol. and Immunol. 1993, 37, 793-799.
48. 48 Bottomly, K., Davis, L.S. and Lipsky, P.E. Measurement of human and murine interleukin 2 and interleukin 4. In: Current Protocols in Immunology - 1994 (Eds Colligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M. and Strober, W.). National Institutes of Health-Wiley and Sons, Inc., USA, 1994, pp. 1:6.3.1-1:6.3.12.
49. 49 Miralles, G.D., Stoeckle, M.Y., McDermott, D.F., Finkelmen, F.D. and Murray, H.W. Th1 and Th2 cell-associated cytokines in experimental visceral Leishmaniasis. Infect. Immun. 1994, 62, 1058-1063.
50. 50 Wunderlich, J. and Shearer, G. Induction and measurement of cytotoxic T lymphocyte activity. In: Current Protocols in Immunology (Eds Colligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M. and Strober, W.) National Institutes of Health-Wiley and Sons, Inc., USA, 1994, pp. 1:3.11.1-3.11.15.
51. + Leishmania major-specific T cell lines or clones which secrete interferon-γ and mediate parasite-specific delayed-type hypersensitivity. Eur. J. Immunol. 1991, 21, 559-567.
52. 52 Sztein, M.B., Wasserman, S.S. and Tacket, C.O. et al. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J. Infect. Dis. 1994, 170, 1508-1517.
53. 53 Langermann, S., Palaszynski, S., Sadziene, A., Stover, C.K. and Koening, S. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature 1994, 372, 552-555.
54. + cytotoxic T cells. J. Exp. Med. 1990, 172, 1083-1090.
55. 55 Flynn, J.L., Weiss, W.R., Norris, K.A., Seifert, H.S., Kumar, S. and So, M. Generation of cytotoxic T-lymphocyte response using Salmonella antigen-delivery system, Mol. Microbiol. 1990, 4, 2111-2118.
56. 56 Brett, S.J., Rhodes, J., Liew, J.Y. and Tite, J. Comparison of antigen presentation of influenza A nucleoprotein expressed in attenuated aroA Salmonella typhimurium with that of live virus. J. Immunol. 1993, 150, 2869-2884.
57. 57 Turner, S.J., Carbone, F.R. and Strunnell, R.A. Salmonella typhimurium ΔaroAΔaroD mutants expressing a foreign recombinant protein induce specific major histocompatibility complex class I restricted cytotoxic lymphocytes in mice. Infect. Immun. 1993, 61, 5374-5380.
58. 58 Harding, C.V. and Song, R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J. Immunol. 1994, 153, 4925-4933.
59. 59 Sztein, M.B., Wasserman, S.S., Tacket, C.O., Edelman, R., Hone, D., Linberg, A.A. and Levine, M.M. Cytokine production and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J. Infect. Dis. 1994, 170, 1508-1517.
60. 60 Sztein, M.B., Tanner, M.K., Polotsky, Y., Orenstein, J.M. and Levine, M.M. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans. J. Immunol. 1995, 155, 3987-3993.
61. 61 Tacket, C.O., Hone, D.M., Losonsky, G.A., Guers, L., Edelman, R. and Levine, M. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine 1992, 10, 443-446.